Important Safety Information
This site is intended for U.S. healthcare professionals only. U.S. healthcare professionals only. Visit patient site

Now Available at Participating Pharmacies

FreeStyle Libre System
The only personal CGM that eliminates fingerstick calibration

Painless2 scan provides real-time glucose readings for insulin dosing
Clinically proven to reduce hypoglycemia versus blood glucose testing3,4
Up to 10-day comfortable sensor wear2
More affordable CGM*

See FreeStyle Libre Pro

FreeStyle Libre Pro:
Professional continuous glucose monitoring (CGM) made easy

Reader stays in office
No fingerstick calibration for patients
Up to 14 days of glucose readings and patterns
Reimbursable procedure with broad coverage

See FreeStyle Libre

Both our personal and professional CGM systems feature the only sensor technology not dependent on the user to maintain accuracy.

Coverage & reimbursement information

FreeStyle Libre systems are more affordable CGM* for your patients

Have a sales representative tell you more

A rep can keep you informed about new and existing Abbott products

* Based on the manufacturers’ list prices. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

† Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

‡ Coverage is limited to patients for whom professional CGM is medically necessary. Individual plan coverage may vary. Always verify coverage criteria and frequency directly with the payer.

Reference: 1. FreeStyle Libre User’s Manual. 2. Data on file. Abbott Diabetes Care. 3. Bolinder, Jan, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet 388.10057 (2016): 2254-2263. 4. Haak, Thomas, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Therapy 8.1 (2017): 55-73. 5. Local Coverage Determination (LCD): Glucose Monitors (L33822). Noridian Healthcare Solutions. Effective January 12, 2017. Public version updated on May 12, 2017.

ADC-05526 Ver 7.0 08/18

You are about to leave for a 3rd party website

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?

Thank you for submitting your details. We will contact you as soon as possible.